Renal proteinuria is associated with promoted renal dysfunction and a shorter survival period in dogs with chronic kidney disease (CKD). Renin angiotensin– aldosterone system inhibitors are primarily used to treat renal proteinuria. In this retrospective, open-label study, we aimed to evaluate the anti-proteinuric and anti-hypertensive effects of telmisartan (angiotensin II receptor blocker) in dogs with proteinuric CKD. A total of 28 dogs with proteinuric CKD were included in the study, all dogs received telmisartan 1 mg/kg q24h, PO. The urine protein-to-creatinine ratio (UPC), urine albumin-to-creatinine ratio (UAC) and systolic blood pressure (SBP) decreased significantly after telmisartan administration (P < 0.05). The median rate of change in UPC, UAC and SBP at Day 120 were − 65.1%, −75.9% and − 9.7%. Ten dogs (36.7%) achieved UPC < 1.0 at Day 120, of which six dogs had UPC < 0.5. A reduction of UPC to ≥50% was achieved in 10 dogs (36%) at Day 45 and 17 dogs (61%) at Day 120. Seventeen dogs (61%) had hypertension at baseline, of which 10 dogs (59%) had SBP < 160 mmHg at Day 120. Two-way repeated measures analysis of variance did not attribute the observed changes in SBP, UPC or UAC to feeding with a renal diet. In conclusion, telmisartan therapy provides anti-proteinuric and anti-hypertensive effects in dogs with proteinuric CKD.

肾蛋白尿与慢性肾病（CKD）狗的肾功能不全和生存期缩短有关。肾素血管紧张素-醛固酮系统抑制剂主要用于治疗肾蛋白尿。在这项回顾性，开放性研究中，我们旨在评估替米沙坦（血管紧张素II受体阻滞剂）对蛋白尿性CKD犬的抗蛋白尿和降压作用。这项研究共纳入了28只具有蛋白尿性CKD的狗，所有狗在24小时内口服替米沙坦1 mg / kg。替米沙坦治疗后尿蛋白/肌酐比（UPC），尿白蛋白/肌酐比（UAC）和收缩压（SBP）显着降低（P <0.05）。在第120天，UPC，UAC和SBP的中位变化率分别为-65.1％，-75.9％和-9.7％。在第120天，有十只狗（36.7％）的UPC <1.0，其中有六只狗的UPC <0.5。在第45天时有10只狗（36％）和在第120天时有17只狗（61％）将UPC降低到≥50％。基线时有17只狗（61％）患有高血压，其中10只狗（59％）在第120天时SBP <160 mmHg。双向重复测量方差分析并未将观察到的SBP，UPC或UAC变化归因于肾脏饮食喂养。总之，替米沙坦疗法可为患有蛋白尿性CKD的狗提供抗蛋白尿和抗高血压的作用。